glp 1 agonist review GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Frontiers | The mechanism and

Strengths and limitations of this review We have comprehensively reviewed the current body of evidence and have combined all data available to us regarding the safety of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation

Trials show these agents can reduce glycated hemoglobin (HbAc) by ~1% or more and induce weight reductions of 510% of body weight in many patients ( [7] ) ( [6] )

Adverse Effects and Long-Term Safety Concerns While GLP-1 receptor agonists have shown significant benefits, their widespread use is limited by potential side effects such as gastrointestinal distress, pancreatitis risk, and concerns over long-term metabolic effects

Franzn, S

One study reported one rat out of 8 expressing human islet amyloid polypeptide (HIP) as a model for diabetes developed pancreatitis when treated with sitaglyptin for 12 weeks (70)

however, GLP-1 had the opposite effect